Lundbeck expands the agreement with Teva to include marketing of Azilect in selected Asian countries
H. Lundbeck A/S announced it had expanded the agreement with Teva Pharmaceutical Industries Ltd. for Azilect® to cover six markets in Asia - China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines.
The Asian market is becoming an increasingly important platform for Lundbeck, as the region experiences rapid growth within the CNS market. With the agreement Lundbeck gains access to six interesting Asian markets all expected to show significant growth within the Parkinson's disease market. Azilect® will be a significant growth driver of Lundbeck's Asian business in general, and especially for China and South Korea. The agreement comes on top of the recent grant of reimbursement in China on two of Lundbeck's key products, Cipralex® and Ebixa®.
As part of the agreement Lundbeck is responsible for conducting the clinical trials and preparing the application filings needed to gain a marketing authorisation in the individual markets. The first launch in one of the markets may potentially occur in approximately one year.
"With the new agreement with our partner Teva, we get an opportunity to expand our already successful work with Azilect®. The pharmaceutical markets in Asia, and the CNS market in particular, is undergoing rapid development, and we see this agreement as a possibility to further strengthen our commercial platform in this promising region," says Ole Chrintz, Senior Vice President, Commercial Operations at Lundbeck. "Azilect® is an important treatment option in an unsatisfied Parkinson's disease market and is the first medication that in clinical trials has shown an effect consistent with the possibility of disease modification in Parkinson's disease. We are glad that we will now be able to offer this effective treatment to the population in the Asian countries."
Specific financial terms remain undisclosed but Lundbeck will pay a share of net sales in the markets to Teva.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Novartis data shows ACZ885 for severe gouty arthritis provided better pain relief and reduced risk of new attacks by up to 68% vs. steroid - Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate
Breakthrough in mapping nicotine addiction could help researchers improve treatment
Study shows how bioactive substance inhibits important receptor - Results from the University of Bonn raise hope for new drugs against cancer and brain diseases
Natural UV radiation in winter not strong enough against SARS-CoV-2 - In winter the virus has a good chance of survival outside
Covestro and Genomatica produce important chemical raw material using biotechnology - Breakthrough for HMDA, widely-used ingredient, paves the way for more sustainable coatings, apparel, adhesives and plastics
How the body’s defenses keep their weapons in check - Protection against deadly infection
Pulmo BioTech Inc. completes bio-distribution studies
Laryngomalacia
